Post Operative Pain Management Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 40.46 Billion |
| Market Size (2029) | USD 53.61 Billion |
| CAGR (2024 - 2029) | 5.79 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Post Operative Pain Management Market Analysis
The Post Operative Pain Management Market size is estimated at USD 40.46 billion in 2024, and is expected to reach USD 53.61 billion by 2029, growing at a CAGR of 5.79% during the forecast period (2024-2029).
Factors fueling the market's growth are the growing number of surgical procedures, the rising number of emergency hospital visits, the increasing demand for non-opioid-based analgesics, and the increasing focus on palliative care.
The growing number of surgical procedures drives the demand for post-operative pain management medications. For instance, according to the Canadian Institutes of Health Information data published in September 2023, in 2021-2022, Canada witnessed over 117,000 hip and knee replacements, marking a 5.9% increase from the preceding year. However, this figure remained below the pre-COVID-19 annual average. With such a huge increase in the number of surgeries performed across several countries, the market for post-operative pain management drugs is expected to exhibit substantial growth, as these medications play a crucial role in managing the pain caused by surgical procedures.
A study published in PubMed Central in January 2022 stated that, according to research conducted by the US Institute of Medicine in June 2022, post-operative pain was a common but often undertreated disease, with 80% of surgery patients experiencing post-operative pain and less than half of these patients reporting appropriate pain control. Furthermore, the study stated that, according to a nationwide survey, 39% of post-operative patients felt severe to terrible pain. Such unmet needs greatly highlight the need for post-operative pain management drugs to optimize palliative care among the patient population, thereby providing lucrative opportunities to prominent players within the market.
Additionally, strategic initiatives by the market players, such as product launches and research and development activities in the field of pain management, are expected to boost the market's growth. For instance, in April 2022, Assiut University started a trial to evaluate the population pharmacokinetics and pharmacodynamics of rectal dexmedetomidine niosomes for post-operative analgesia in pediatric cancer patients undergoing bone marrow biopsy and aspiration compared to the intravenous and rectal plain formulation.
In April 2022, Acadia Pharmaceuticals Inc. announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. The primary endpoint, a comparison of cumulative pain intensity scored over 24 hours between the ACP-044 1600 mg once daily, the ACP-044 400 mg four times daily, and the placebo treatment arms, was not met.
Thus, factors such as the rising number of surgical procedures and strategic initiatives by market players are expected to boost market growth over the forecast period. However, concerns about the overuse of opioids are a major factor restraining the market's growth.
Post Operative Pain Management Market Trends
The Non-steroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Hold a Significant Share of the Market
The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold a significant market share by drug class. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain, reduce inflammation, and bring down high body temperatures.
The major factors fueling the segment's growth are the implementation of strategic initiatives by the market players, the growing demand for NSAIDs owing to their advantages over other drugs, and the increasing number of surgical procedures. For instance, in March 2022, Health Canada issued a Notice of Compliance (NOC) to commercialize Heron Therapeutics' ZYNRELEF (bupivacaine, which is an amide local anesthetic, and meloxicam, which is a non-steroidal anti-inflammatory drug (NSAID) extended-release solution) for instillation into the surgical wound for post-operative analgesia after a bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.
In March 2024, Eyenovia, in collaboration with its Taiwan-based partner, Formosa Pharmaceuticals, disclosed the FDA's approval of its clobetasol propionate 0.05% eye drops. These drops are meant to treat post-operative inflammation and pain following eye surgery.
Thus, the segment is expected to grow significantly over the forecast period due to the various strategic activities by the key players and the rise in acceptance of NSAIDs for post-operative pain management.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
The United States is expected to hold a significant share of the market in North America. The major factors bolstering the market's growth are the growing number of surgical procedures, the surge in awareness regarding post-operative pain management drugs, the increasing number of product approvals, and the rising focus on palliative care.
The increase in the number of surgeries in the country is expected to propel the growth of the market. For instance, Cedars-Sinai data updated in January 2022 showed that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass or bypass surgery, was the most common type of heart surgery. More than 300,000 people in the United States have successful bypass surgery each year. Such statistics are likely to increase the demand for post-operative pain management medications within the country, thereby boosting the market's growth.
Several guidelines and recommendations have been put forward by the healthcare authorities in the region, which is contributing to market growth. For instance, in March 2024, the American Academy of Orthopaedic Surgeons released updated guidelines for the treatment of hip osteoarthritis, which mentioned that pharmacologically managing hip osteoarthritis (OA) often involves the moderate recommendation of intra-articular corticosteroids. Additionally, intra-articular corticosteroids improve short-term function and reduce pain in patients with symptomatic hip OA.
Thus, owing to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
Post Operative Pain Management Industry Overview
The post-operative pain management market is fragmented, with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Pfizer Inc., AbbVie, GlaxoSmithKline PLC, Heron Therapeutics, and AFT Pharmaceuticals.
Post Operative Pain Management Market Leaders
-
AbbVie (Allergan)
-
Heron Therapeutics
-
Pfizer Inc.
-
AFT Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Post Operative Pain Management Market News
- April 2024: Forte Healthcare introduced Ficoxil, a flavored, chewable NSAID tailored to alleviate pain and inflammation in dogs, specifically targeting osteoarthritis and post-operative recovery.
- February 2024: Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, unveiled its latest product in the US market, COMBOGESIC IV, an injection combining acetaminophen and ibuprofen. COMBOGESIC IV is an intravenous pain relief medication devoid of opioids. It combines 1,000 mg of acetaminophen with 300 mg of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID).
- April 2023: Cali Biosciences Co. Ltd initiated Phase III studies of its core product, CPL-01 (long-acting ropivacaine). Dosing in hernia patients had already started, and dosing in bunion patients was scheduled to start the following month.
Post-Operative Pain Management Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Number of Surgical Procedures
- 4.2.2 Increasing Demand for Non-Opioid Based Anaelgesics
- 4.2.3 Increasing Focus Towards Palliative Care
-
4.3 Market Restraints
- 4.3.1 Concerns Pertaining to the Overuse of Opioids
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value -USD)
-
5.1 By Drug Class
- 5.1.1 Opioids
- 5.1.2 Non-steroidal anti-inflammatory drugs (NSAIDS)
- 5.1.3 Cyclooxygenase-2-selective inhibitors (COX-2) inhibitors
- 5.1.4 Other Drug Classes
-
5.2 By Route of Administration
- 5.2.1 Injectable
- 5.2.2 Oral
- 5.2.3 Topical
- 5.2.4 Other Routes of Administration
-
5.3 By Distribution Channel
- 5.3.1 Hospital Pharmacies
- 5.3.2 Retail Pharmacies
- 5.3.3 Other Distribution Channels
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie (Allergan)
- 6.1.2 Heron Therapeutics
- 6.1.3 Cali Biosciences
- 6.1.4 Innocoll
- 6.1.5 Bayer AG
- 6.1.6 Haleon PLC (GSK)
- 6.1.7 Pacira Pharmaceuticals Inc.
- 6.1.8 Johnson & Johnson (Janssen Pharmaceuticals)
- 6.1.9 AFT Pharmaceuticals
- 6.1.10 Alembic Pharmaceuticals
- 6.1.11 Cipla Inc. (InvaGen Pharmaceuticals Inc.)
- 6.1.12 SiteOne Therapeutics
- 6.1.13 Pfizer Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPost Operative Pain Management Industry Segmentation
As per the report's scope, post-operative pain is defined as a complex response to tissue trauma post-surgical procedures. It comprises both surgery-related pain and pain linked with central nervous system hypersensitivity. The purpose of post-operative pain management medications is to minimize adverse effects while reducing or eliminating pain and discomfort.
The post-operative pain management market is segmented by drug class, route of administration, distribution channel, and geography. By drug class, the market is segmented into opioids, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2-selective inhibitors (COX-2) inhibitors, and other drug classes. By route of administration, the market is segmented into injectable, oral, topical, and other routes. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report offers the value (USD) for all the above segments. The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
| By Drug Class | Opioids | |
| Non-steroidal anti-inflammatory drugs (NSAIDS) | ||
| Cyclooxygenase-2-selective inhibitors (COX-2) inhibitors | ||
| Other Drug Classes | ||
| By Route of Administration | Injectable | |
| Oral | ||
| Topical | ||
| Other Routes of Administration | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Other Distribution Channels | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Post-Operative Pain Management Market Research FAQs
How big is the Post Operative Pain Management Market?
The Post Operative Pain Management Market size is expected to reach USD 40.46 billion in 2024 and grow at a CAGR of 5.79% to reach USD 53.61 billion by 2029.
What is the current Post Operative Pain Management Market size?
In 2024, the Post Operative Pain Management Market size is expected to reach USD 40.46 billion.
Who are the key players in Post Operative Pain Management Market?
AbbVie (Allergan), Heron Therapeutics, Pfizer Inc. and AFT Pharmaceuticals are the major companies operating in the Post Operative Pain Management Market.
Which is the fastest growing region in Post Operative Pain Management Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Post Operative Pain Management Market?
In 2024, the North America accounts for the largest market share in Post Operative Pain Management Market.
What years does this Post Operative Pain Management Market cover, and what was the market size in 2023?
In 2023, the Post Operative Pain Management Market size was estimated at USD 38.12 billion. The report covers the Post Operative Pain Management Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Post Operative Pain Management Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Post-Operative Pain Management Industry Report
The Post-Operative Pain Management Market Report provides a comprehensive industry overview, detailing the segmentation by drug class, route of administration, distribution channel, and geography. The market analysis covers various drug classes, including opioids, NSAIDs, COX-2 inhibitors, and other drug classes. It also examines different routes of administration such as injectable, oral, topical, and other routes. The distribution channels analyzed include hospital pharmacies, retail pharmacies, and other distribution channels.
The industry report offers valuable industry information and insights into market trends, market segmentation, and market value. It includes a detailed industry analysis, highlighting the market growth, market leaders, and market outlook. The report also features a market forecast, providing a market review and market predictions for the post-operative pain management market.
The report includes industry statistics and industry research, offering a thorough understanding of the market data and industry size. The market forecast outlook extends to a specified period, providing a historical overview and future projections. The report is available as a free report PDF download, serving as a report example for those interested in industry sales and market research.
Overall, the industry reports and market report provide a detailed market overview, covering all aspects of the post-operative pain management market. The research companies involved have ensured that the report is comprehensive, offering valuable insights and data for stakeholders.
